Haemonetics Overview
Latest P/E ratio for Haemonetics: 42.64 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow42.64
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for HAE is 42.64. That is above the Healthcare sector average of 26.36. Investors often review this figure alongside Haemonetics's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, HAE currently prints 42.64 for P/E ratio, while the sector average sits near 26.36. That is roughly 61.8% above the sector mean. Large gaps often invite a closer look at Haemonetics's growth, margins, and balance sheet.
A P/E ratio of 42.64 for Haemonetics is not 'good' or 'bad' on its own. Compare it with the peer average (26.36) and with HAE's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting HAE's P/E ratio (42.64), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Haemonetics's P/E ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
